Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves ColoSense – a noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test – Geneoscopy Inc

Written by | 1 Jun 2024

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that the FDA approved its noninvasive colorectal cancer screening test,… read more.

Offering both colonoscopy and at-home tests doubled colorectal cancer screening

Written by | 19 May 2024

The rate of colorectal cancer screenings more than doubled when patients were given a choice between which type of screening they wanted—a take-home kit or colonoscopy—compared to those… read more.

Diabetes drugs appear to lower colorectal cancer risk

Written by | 16 Dec 2023

Glucagon-like receptor agonists (GLP-1 RAs), a class of type 2 diabetes drug treatments, appear to also reduce the risk of colorectal cancer (CRC) researchers reported on Dec. 7,… read more.

MHLW (Japan) approval for Phesgo, the fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast and colorectal cancer – Chugai

Written by | 30 Sep 2023

Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for Subcutaneous Injection MA, IN… read more.

European Commission approves Lonsurf in combination with bevacizumab for the third-line treatment of metastatic colorectal cancer – Servier + Taiho

Written by | 7 Aug 2023

Taiho Pharmaceutical announced that its partner Servier, has won European regulatory approval for Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the third-line treatment of metastatic colorectal… read more.

Publication of phase III FRESCO-2 results evaluating fruquintinib in patients with previously treated colorectal cancer in The Lancet – Takeda and HutchMed

Written by | 25 Jun 2023

Takeda and HUTCHMED (China) Limited announced that results of the Phase III FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in… read more.

Efficacy of fruquintinib confirmed in refractory metastatic colorectal cancer

Written by | 19 Jun 2023

In patients with refractory metastatic colorectal cancer, fruquintinib treatment has resulted in a significant improvement in overall survival compared with placebo. Researchers reported this finding on June 15,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.